Cargando…
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
BACKGROUND: Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and late stage breast cancer. However, clinical...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861058/ https://www.ncbi.nlm.nih.gov/pubmed/20346177 http://dx.doi.org/10.1186/1757-2215-3-7 |